RIP: After burning through $463M, StemCells’ corpse is bought out for the public shell
Back at the end of May, Newark, CA-based StemCells $STEM joined the walking dead of biotech. Running out of cash, its Phase II spinal cord study failing badly, the executive team tossed in their cards and started to push away from the table.
Said CMO Stephen Huhn:
Unfortunately, the Company does not have the resources to implement changes in our development program to permit further investigation.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.